Table 2. Demographics and clinical characteristics of validation cohort with comparisons to primary cohort subsets.
SARS-CoV-2 validation (n = 89) |
Validation-primary COVID-19 comparison |
Validation-healthy comparison |
Validation-influenza comparison |
|
Demographics | ||||
Means ± SD (range) age, in years |
61 ± 17 (19–92) | P = 1, N.S. | P < 0.001, OR = 0.87 | P = 0.041, OR = 0.93 |
Female | 39% (35/89) | P = 1, N.S. | P = 1, N.S. | P = 1, N.S. |
Ethnicity | ||||
African American | 74% (66/89) | – | – | – |
White | 25% (22/89) | P = 1, N.S. | P = 0.069, N.S. | P = 1, N.S. |
Other | 1% (1/89) | P = 1, N.S. | – | P = 1, N.S. |
Clinical characteristics | ||||
Mean (IQR) body mass index |
28.6 (24–33) | – | – | |
Mean (IQR) symptom duration at study enrollment, in days |
7.5 (2–9) | P = 0.958, N.S. | P = 0.635, N.S. | |
Hospital admission | 94% (84/89) | P = 0.958, N.S. | P = 0.043, OR = 0.046 | |
ICU admission | 48% (43/89) | P = 0.10, N.S. | P = 1, N.S. | |
Intubation and mechanical ventilation |
27% (24/89) | P < 0.001, OR = 19.03 | P = 0.893, N.S. | |
In-hospital death | 17% (15/89) | P = 0.509, N.S. | P = 1, N.S. | |
Comorbidities | ||||
Immunocompromised | 8% (7/89) | P = 1, N.S. | P = 0.347, N.S. | |
Chronic lung disease | 16% (14/89) | P = 0.017, OR = 5.9 | P = 0.049, OR = 11.69 | |
Chronic heart failure | 15% (13/89) | P = 1, N.S. | P = 0.817, N.S. | |
End-stage renal failure | 2% (2/89) | P = 1, N.S. | P = 1, N.S. | |
Diabetes mellitus | 44% (39/89) | P = 1, N.S. | P = 1, N.S. | |
Active cancer | 3% (3/89) | P = 0.893, N.S. | P = 0.387, N.S. |